X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
News provided byX4 Pharmaceuticals
Sep 19, 2023, 8:00 AM ET
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.
Details are as follows:
Conference: Cantor Global Healthcare Conference
Date: Tuesday, September 26, 2023
Time: 4:55 PM ET
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
Brett Whelan (media)
NOTE: This content is not written by or endorsed by "KNWA and KFTA", its advertisers, or Nexstar Media Inc.